We’re Zeroing in on the ‘Holy Grail’ of COVID-19 Immunity

July 21, 2021

(The Atlantic) – In recent weeks, the correlate community has been buzzing louder than ever. Scientists are on the cusp of confidently defining some correlates of protection against symptomatic disease for the COVID-19 vaccines. If confirmed, these correlates could revolutionize the way we tackle SARS-CoV-2 immunization: Vaccine makers testing a new inoculation may no longer need to follow tens of thousands of people for many months to test their product’s protection. Instead, they could inject just a few hundred people, snag some drops of blood, and see if the elusive correlate is met. That’s how we tee up new flu vaccines every year without the rigmarole of gargantuan clinical trials. (Read Full Article)